Anthony Keech
National Health and Medical Research Council, Australia · NHMRC Clinical Trials Centre, The University of Sydney
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anthony Keech as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:48 UTC. Open this list on ClinicalTrials.gov
- N/ANCT04128475 · Observational Study of Cardiovascular Disease.University of Sydney · terminated · Cardiovascular Diseases, Cardiovascular Morbidity, Coronary Heart Disease · study chair
- Ph3NCT03998319 · A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.University of Sydney · recruiting · STEMI, Elevated IMR (>32) · study chair
- Ph3NCT01320345 · The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.University of Sydney · active not recruiting · Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:48 UTC. The ranking covers the 200 most relevant of 116 PubMed records, and a shared surname and initials can bring in a namesake. All 116 on PubMed
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.N Engl J Med · 20174,774 citationsRCR 180.8
- 2,466 citationsRCR 61.7
- 845 citationsRCR 22.5
- Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.Circulation · 2019767 citationsRCR 34.9
- 598 citationsRCR 25.1
- 540 citationsRCR 19.4
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.Lancet Diabetes Endocrinol · 2017477 citationsRCR 17.4
- 424 citationsRCR 10.9
- Cognitive Function in a Randomized Trial of Evolocumab.N Engl J Med · 2017388 citationsRCR 13.8
- Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults.J Clin Invest · 1996358 citationsRCR 11.5